Telehealth is the channel that built the compounded GLP-1 economy. Hims & Hers, Ro, LifeMD, Eucalyptus, MedVi, JustCare Health, BoomRx, and similar programs scaled to billions in revenue on top of FDA-declared shortages of semaglutide and tirzepatide between 2022 and 2024.
The post-shortage rules have forced re-routing. Some programs pivoted to additive formulations to stay inside 503A patient-specific compounding rules; others moved into sermorelin, peptide stacking, and broader peptide therapy. Most have lobbied around the Outsourcing Facilities Association litigation and the April 30, 2026 FDA proposal to exclude branded GLP-1s from the 503B bulks list. The University of Colorado secret-shopper study quantified the gap — 65–69 of 74 weight-loss clinics still sold compounded GLP-1s as of April 2026.
Stories here cover platform-level pivots, partnership news, and the regulatory exposure.
A JAMA study led by a Yale researcher, reported by STAT on July 6, had an investigator pose as a patient across 49 websites selling branded or compounded semaglutide or tirzepatide between August and December 2025. Of those, 45 sites (91.8%) issued a prescription, with a median time to prescription of one day or less and often minimal clinical evaluation. The findings sharpen concerns about telehealth prescribing standards as enforcement against compounded GLP-1s tightens.
The Pep Club, a direct-to-consumer telehealth platform co-founded by entrepreneur Greg Yuna (CEO) and Gabriella Shak, publicly launched Tuesday June 30, 2026 at thepepclub.com with a full-stack model pairing prescription medication therapy and physician-guided peptide protocols with at-home biomarker testing. The platform spans more than a dozen categories including weight management (GLP-1 prescriptions), hormone optimization (testosterone, thyroid), sexual health (PT-141, sildenafil, tadalafil), hair restoration (finasteride, GHK-Cu, oral minoxidil), skin and acne (tretinoin, hyaluronic acid, cosmetic peptides), IV and vitamin support, peptides (BPC-157, TB-500, ipamorelin, sermorelin among the compounded offerings), and longevity. All protocols are reviewed and supervised by licensed clinicians and fulfilled through licensed pharmacy partners. The differentiator is the at-home capillary biomarker collection device that lets patients submit lab-quality panels for personalization and monitoring. Yuna, co-founder and CEO: 'When you combine real at-home testing with both prescription and peptide therapy under licensed clinical supervision, you can actually personalize treatment to the individual.' The platform launches into a competitive telehealth market that already includes Hims & Hers, LifeMD, Henry Meds, and Ro; the Pep Club differentiator is the peptide-plus-biomarker integration.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
AMC Defense Law's June 2026 'Justice Watch' note read the peptide enforcement signal: compounding pharmacies receiving warning letters and losing licenses, telehealth companies facing criminal indictments, and bulk-substance vendors under federal scrutiny. The FDA has issued more than 50 warning letters to peptide vendors and compounders in 2024-2025, and the agency has signaled an aggressive 503A/503B stance heading into the July 23-24 PCAC meeting that will rule on whether seven peptides return to legal compounding status.
Hims & Hers' proxy report ahead of the June 11 virtual annual meeting shows 2025 revenue at $2.35 billion (up 59%), 2.5 million-plus subscribers, $318 million adjusted EBITDA, and $300 million operating cash flow. The company's GLP-1 pivot now leans on the Lilly tie-up (Zepbound vials and KwikPens, plus Foundayo via LillyDirect; Bank of America lifted its price target to $32) and the renewed Novo Nordisk partnership for branded Wegovy. The compounded-semaglutide business is winding down ahead of the FDA 503B exclusion that becomes effective after the June 29 comment window closes.
Six weeks ahead of the FDA's June 29 closing date for public comments on the April 30 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide, the compounded-GLP-1 telehealth segment has settled into a defensive pricing structure. Ozari Health's May 19 launch at $86/month compounded semaglutide and $120/month compounded tirzepatide established the floor; comparable platforms have held prices steady at $99-249/month rather than competing further on price. The Saturday market sentiment is split: bull case is that the FDA's final determination could grandfather existing 503A patients under a transition window, leaving cash-pay compounded GLP-1 viable through 2027; bear case is that the BSR Intelligence-documented 90% YoY drop in compounded semaglutide shipments accelerates as 503B compounding ends, with only the smallest-volume 503A pharmacies remaining. Patient migration toward branded Wegovy via Novo's Hims & Hers branded-distribution channel (125K shipments in six weeks) is the natural off-ramp.
Hims & Hers Health announced May 18 the pricing of an upsized $350M aggregate principal amount of 0.00% convertible senior notes due 2032, with settlement May 21. Initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal — a conversion price of approximately $29.53 per share, representing a 32.5% premium over the $22.29 close on May 18. The capped call cap price was set at approximately $50.15 per share (125% premium). Initial purchasers granted an option to buy up to an additional $52.5M in notes within 13 days. Proceeds support international expansion strategy and the proposed acquisition of Eucalyptus (Australian-based digital health platform with peptide and weight-management presence in Australia, UK, and Germany) expected to close mid-2026. The convertible structure preserves cash for the international rollout while the Novo Nordisk branded distribution partnership scales US Wegovy supply.
Ozari Health, a New York-based telehealth company, launched a nationwide platform on Tuesday May 19, 2026 offering compounded semaglutide starting at $86/month and compounded tirzepatide starting at $120/month, with branded options (Wegovy, Ozempic, Mounjaro, Zepbound) available through the same channel. Patients complete an online intake, get evaluated by state-licensed providers, and receive prescriptions filled by partner compounding pharmacies including Hallandale Pharmacy and VialsRX — the multi-pharmacy partner structure differentiates Ozari from telehealth platforms that work with a single compounding partner. Ozari pricing sits at the floor of the compounded GLP-1 market; comparable platforms (Sesame, Henry Meds, Wisp) range $99-249/month for compounded semaglutide. The launch lands as the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comments closing June 29) puts long-term compounding-pharmacy access in question.
Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.
In its fourth commercial week (April 27–May 1), Eli Lilly's Foundayo (orforglipron) recorded 7,335 prescriptions per IQVIA, Citi told clients May 8, calling the early launch 'off to a solid start' and modeling $146M in Q2 revenue and $1.6B for full-year 2026. Citi flagged that IQVIA captures retail and partial telehealth data but likely understates Lilly Direct and the 12+ telehealth firms representing roughly 35% of launch volume; Lilly executives have cited 20,000 patients now on Foundayo. For comparison, Citi's same note pegged Wegovy pill at 440,410 prescriptions in the week ending May 1, with oral semaglutide accounting for 33% of all Novo obesity referrals.
CNBC's May 6 Wegovy-Q1 piece documented LifeMD new-patient volume jumping from 300–400 per day before the Wegovy pill January 5 launch to 600–1,000 per day after, with the telehealth platform crediting the pill format and improved insurance coverage for unlocking a wave of GLP-1-curious patients who had not previously committed to injectables. LifeMD has been one of the most exposed independent pure-play telehealth obesity platforms during the Novo channel-expansion era, and its data point feeds the broader 'oral GLP-1 expands the market' thesis that Lilly's Foundayo team also referenced on the April 30 Q1 call (where 80% of Foundayo patients were new to the GLP-1 class).
Hims & Hers reports Q1 2026 results May 11 after market close. Company guidance: $600–625M revenue (2–7% YoY) and $35–55M adjusted EBITDA (~7% margin), with Q1 carrying a roughly $65M timing impact from the weight-loss shift to 503A fulfillment. Outlook (ex-Eucalyptus) is $2.7–2.9B revenue and $300–375M EBITDA. Hims also launched Testosterone Rx+ — a once-daily pill for low-libido idiopathic hypogonadism — as a non-GLP-1 specialty addition, signaling the wider longevity and peptide play the company has telegraphed for 2026. The California peptide-manufacturing facility acquired in February 2025 sits as a post-PCAC option for producing reclassified Category 1 peptides if the July meeting clears the path.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
Hims & Hers shares climbed roughly 9% in early-week trading from $28.82 to $31 ahead of the company's May 11 Q1 2026 earnings, extending a five-session run that has lifted the stock about 49%. The catalysts: renewed FDA interest in peptides via the upcoming July PCAC meeting and the company's Novo Nordisk collaboration providing branded Wegovy and Ozempic access. Hims also flagged a 2026 longevity specialty launch covering peptides, coenzymes, and GLP/GIP treatments, and continues to invest in the California peptide-manufacturing facility acquired in February 2025 — which could pivot to producing reclassified Category 1 peptides if the July PCAC clears the path.
WeightWatchers announced May 1 that its Med+ platform and affiliated medical groups will begin offering Ozempic pill (oral semaglutide) for clinically eligible members with type 2 diabetes. Many eligible members can access the medication for as low as $25/month with pharmacy benefits. The expansion adds a once-daily oral GLP-1 alongside the existing Med+ portfolio of clinically supervised weight-management and metabolic-health treatments, giving WW a foothold in T2D care to complement its weight-loss positioning.
Hello Peptide announced an expansion of its digital platform HelloPeptide.net on April 30, positioning it as a research-aligned consumer education resource for adults navigating GLP-1 and peptide-therapy decisions. The launch is timed to a documented surge in consumer search and telehealth inquiries that followed the FDA's April 22 Category 2 removal of 12 peptides and the upcoming July 23–24 PCAC meeting. The platform sits alongside FormBlends' 2026 State of Peptides report and a wave of legacy-media safety primers as the post-restriction information ecosystem takes shape.
An investor-facing April 2026 deep dive analyzes Hims & Hers' transformation from compounded GLP-1 distributor to dual-supplier branded telehealth platform after the Novo Nordisk settlement (March 9, 2026), the Eli Lilly partnership expansion (April 23), and the FDA Category 2 peptide reclassification. The piece argues the California peptide manufacturing facility acquired in 2025 — originally for compounded GLP-1s — could pivot to producing reclassified peptides like BPC-157, TB-500, and KPV if July's PCAC clears the path.